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ABSTRACT
OBJECTIVE: To describe how lawsuits, which demand the supply of drugs, 
impact on elements of the national drug policy. 
METHODS: This is a desk-based study using qualitative and quantitative 
methods. All legal proceedings brought by citizens against the Municipal 
Secretary of State of Sao Paulo, relating to the supply of drugs in 2005 were 
analyzed. A standardized form was used to collect data, with a view to carrying 
out an exploratory analysis. 
RESULTS: A total of 170 cases relating to the supply of drugs were brought 
against the Municipal Secretary of State. The National Health System (SUS) 
was the source for 59% of the prescriptions: 26% from the municipal level, 
33% from other levels. Cancer and diabetes were the diseases most commonly 
involved (59%). About 62% of drugs requested are on the lists of SUS services. 
Total expenditure was R$876,000 (Brazilian Reais), covering only non-selected 
items (i.e. those which are not included in the Municipal Register of Essential 
Medicines), 73% of which could be substituted. Of the total expenditure, 75% 
was spent on purchasing anticancer drugs, for which further clinical trials 
are required to prove their effectiveness. Two of these medicines were not 
registered in Brazil. 
CONCLUSIONS: The majority of demands for drugs that have led to legal 
proceedings could be avoided if two SUS directives were followed, namely the 
organization of oncology services and the observance of reporting on essential 
medicines. Failure to do so causes a breakdown in the National Drug Policy, in 
equality of access and in the rational use of drugs within the National Health 
System. 
KEYWORDS: National Drug Policy. National Policy on Pharmaceutical 
Care. Unifi ed Health System. Legal Decisions.
INTRODUCTION
International trade in medicines increased rapidly between 1980 and 1999, rising 
from US$5 billion to US$120 billion during that period. Within this market, 
a smaller number of multinational companies dominate the global production 
and sale of medicines. Ten of these companies are responsible for almost half 
of all sales and this concentration has grown considerably since 1987. Changes 
between 1985 and 1999 show that the value of drug production has increased 
four times more quickly than world income, although this has not translated 
into greater access to medicines amongst the population. In 1999, the 15% of 
the world’s population who live in high-income countries were responsible for 
buying and consuming medicines equivalent to 90% of total world expenditure 
on drugs. The USA alone, in 2000, made up 52% of this market, while low-
income countries’ share of global consumption of drugs dropped from 3.9% 
in 1985 to 2.9% in 1999.13
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In Brazil, it was estimated that in 2000, the number of 
people who did not have access to drugs was 70 mil-
lion, representing approximately 41% of the population 
in that year. This is one of the main challenges to the 
public health system.
The Brazilian Health System, SUS (from the Portu-
guese acronym), was set up under the Federal Constitu-
tion of 1988 and established in law in 1990. Under the 
SUS, universal equality of access is guaranteed, and 
health services and systems are integrated. The right 
to pharmaceutical services, including therapy, was also 
anticipated but was not regulated and only in 1998 was 
the National Medicines Policy (PNM) published. This 
document included policy proposals for guaranteeing 
safety, effectiveness and quality of drugs, the promo-
tion of rational use, and universal access to medicines 
considered essential. The directives established under 
the PNM included the drawing up of essential drug 
lists, regulation of drug hygiene, and the promotion of 
their rational use, the reorganization of pharmaceutical 
services, scientifi c and technological development, the 
promotion of drug production, safety guarantees, the 
effectiveness and quality of drugs, and the development 
and training to human resources.*
Due to the size of Brazil and regional differences in 
morbidity and mortality indicators, the management of 
SUS is divided between the three spheres of govern-
ment. For this reason, guidelines set out how state- and 
municipal-level governments should select medicines 
for their regional lists, based on a national report.**
Health services can be operated by the private sector 
and, as occurs in the municipality of São Paulo, private 
service providers often write prescriptions that are then 
supplied by SUS pharmacies. This practice goes against 
the policy of integration of actions and services of the 
unifi ed system, since the supply of drugs should only 
be guaranteed through prescriptions originating from 
SUS.***
In spite of the advances made by SUS since its cre-
ation, the State is still falling short in guaranteeing 
access to essential drugs for the Brazilian population. 
At present, one particular issue trend is giving rise to a 
breakdown in Brazilian medicines policy and as such 
is diminishing the amount of resources available for 
drug purchasing. It has become common for citizens to 
make legal claims, through the judicial system, for the 
acquisition of drugs which do not appear on the lists 
of essential medicines.6
Thus, bearing in mind the distortions that this practice 
can cause, the present study aimed at describeingthe 
effects that legal proceedings relating to demands for 
the supply of drugs, have on elements of the National 
Medicines Policy.
METHODS
This is a desk-based study using qualitative and quanti-
tative methods. The unit of analysis of the study is the 
lawsuit, brought by the citizen against the Municipal 
Secretary of Health of São Paulo (SMS-SP, in the 
Portuguese), and in particular those that are within the 
judicial system to demand the supply of drugs required 
by patients. Only those legal proceedings that were 
brought between January and December 2005 and re-
lated to demands for drugs were evaluated. In addition, 
the researchers used information relating to on-going 
proceedings sourced from the Juridical Advisory and 
the Support Division of SMS-SP.
The study used a standardized form for collecting data 
relating to cases that were successfully brought, so as 
to allow for a subsequent exploratory analysis. The 
variables under consideration were: declared illnesses, 
types of therapeutic groups of medicines demanded, the 
existence of alternatives in the São Paulo Municipal 
Register of Essential Medicines (REMUME, in the 
Portuguese),**** the register of medicines at Agência 
Nacional de Vigilância Sanitária (ANVISA – the Bra-
zilian Health Surveillance Agency) and at the USA’s 
Food and Drug Administration (FDA), and the existence 
of scientifi c evidence upon which recommendations for 
use of the drugs were founded.
Verifi cation of the scientifi c evidence of the effective-
ness and safety of drugs was carried out by means 
of a systematic review of studies in the database of 
the Cochrane Centre of Brazil***** and the existing 
monographs in the Micromedex database.****** This 
same database was used to collect data regarding the 
approval of medicines by the FDA for the cases referred 
to in the lawsuits. Information about the register of 
medicines in Brazil were obtained from the Anvisa 
* Câmara dos Deputados. Relatório da Comissão Parlamentar de Inquérito destinada a investigar os reajustes de preço e a falsifi  cação de 
medicamentos, materiais hospitalares e insumos de laboratórios. Brasília (DF); 2000.
** Ministério da Saúde. Política nacional de medicamentos. Brasília (DF); 1999.
***Santos L. Saúde: conceito e atribuições do Sistema Único de Saúde. Available from: http://jus2.uol.com.br/doutrina/texto.asp?id=7378 
[Accessed on 17 Jan 2006].
**** The municipality of São Paulo adopted the directives of the PNM and of the World Health Organization (WHO) with regards to decisions 
on the access and rational use of drugs. According to the WHO, essential medicines are those that meet the priority health needs of the popu-
lation; they are chosen on the basis of their relevance to public health, proof of their safety and effectiveness and their cost-effectiveness.
***** Cochrane Library. Available from: http://cochrane.bireme.br [Accessed on 5 Jan 2006]
****** These databases provide evidence-based information, used particularly for the basis of a recommendation or rejection of a drug for a 
specifi c illness. There is no free access via the Internet. In Brazil, access is available in São Paulo at the Regional Medical Library, BIREME of 
the Pan-American Health Organization.
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database of Drugs and Blood Products,* between 10 
and 16 January 2006.
The prescriptions were classifi ed according to origin 
as follows: 1) SUS services (prescriptions originating 
from the SUS network): SMS-SP or other; 2) Private 
services: Contracted by SUS (service provision to SUS) 
or Not contracted (other).
The prescribed drugs were distributed across fi ve cat-
egories, as follows: 1) High cost – drugs dispensed by 
SUS through the Program for Exceptional Dispensa-
tion of Medicines, run by the state- and federal-level 
governments; 2) REMUME – drugs dispensed by SUS 
under the responsibility of SMS-SP; 3) Anti-cancer 
drugs – medicines fi nanced by SUS for patients treated 
under the network of private contractors; 4) REMUME 
active ingredients – drugs whose active ingredients ap-
pear on the list, but which do not appear on the list in 
their pharmaceutical form or in the required dosage for 
treatment; 5) Non-selected – drugs which do not make 
up the REMUME or other SUS programs.
The counting of the medicines requested and their 
classifi cation were carried out for all legal cases. Some 
data were repeated, since certain drugs were requested 
in more than one case.
The drugs that are not listed on REMUME and other SUS 
lists were drawn up and classifi ed under the Anatomical 
Therapeutic Chemical System up to level 3 (therapeutic 
subgroup).** Those defi ned as alternative therapies were 
taken to include those drugs requested through legal pro-
ceedings which belong to the same therapeutic subgroup 
as others that appear on the SUS lists.
The measurement of total expenditure on medicines 
demanded through legal means was carried out only for 
non-selected items. The REMUME items are usually dis-
pensed through municipal health units and for this reason, 
the cases were forwarded to the coordinating bodies so 
that they could manage the supply of these drugs.
Amounts spent on non-selected drugs were taken from 
the administrative document of the registry of budgetary 
expenditure (note of allocation), appearing in the legal 
proceedings. In addition, the documents issued by the 
Juridical Advisory of SMS-SP were used, with permis-
sion for their use granted by the Support Divison.
The residential addresses of those individuals bringing 
legal cases for the acquisition of medicines were super-
imposed upon a map of social exclusion and inclusion 
in the municipality of São Paulo.***
The research project was submitted to and approved 
by the Committees for Ethics in Research of the Uni-
versidade Federal de São Paulo and for the Municipal 
Secretariat of Health of São Paulo.
RESULTS
In 2005, 170 cases were brought against the municipal 
government to demand the supply of drugs. In 78% of 
these cases (N=133), the data collection form had been 
completed in full. For the remaining cases, the entire 
proceeding was not available for consultation and it 
was only possible to obtain information about the drugs 
demanded, the illness of the plaintiff and the amounts 
spent in acquiring the drugs.
Total expenditure on drugs from these cases was 
R$876,000 Brazilian Reais (or $374,000 US Dollars). 
Of this, only the additional expense incurred by the 
SMS-SP in buying the drugs demanded through the 
lawsuits was considered. The amount relating to medi-
cines that were requested through lawsuits but that are 
regularly dispensed at the municipal health services 
was not calculated.
Of the 133 completed forms, 66% of cases include infor-
mation about the age of the plaintiffs and 79% their occu-
pation. In addition, 90% provided a copy of the medical 
prescription and 54% of plaintiffs were represented by 
legal professionals not working for the State. The profi le 
of the claimants and the origin of the prescription that 
gave rise to the case are detailed in Table 1.
The majority of legal proceedings for the acquisition 
of drugs from the SMS-SP was brought by women 
(63.5%). With regard to age range, more than half of the 
cases were brought by claimants aged between 0 and 
19 (30.7%) and 70 and 79 (23.9%). A total of  74.2% 
of claimants declared their occupation to be retired, 
pensioner, unemployed, student or home maker. Pre-
scriptions originated from SUS services made up 59% 
and 13% from SUS contractors.
Figure 1 shows the illnesses most commonly mentioned 
to justify the legal case for the acquisition of drugs. The 
fi gure shows that the illness most commonly involved 
in such legal proceedings was diabetes (37%), followed 
* Agência Nacional de Vigilância Sanitária. Banco de dados de Medicamentos. Available from: http://www.anvisa.gov.br/medicamentos/ban-
co_med.htm [Accessed on 10 Jan 2006]
** WHO Collaborting Centre for Drug and Statistics Methodology. Anatomical Therapeutic Chemical classifi cation. Available at http://www.
whocc.no/atcddd/ [Accessed on 7 Jan 2006]
*** The composition of the index for social exclusion and inclusion (Iex) is attained through summing indicators from various categories such 
as, the indicator for autonomy, quality of life, human development, and equality and varies from 1 to -1. The closer the index to -1, the greater 
the degree of social exclusion of the population who live in the region or micro-region. More information can be found at: Centro de Estudos 
de Desigualdades Sócio-Territoriais [Internet site]. Mapping social exclusion/inclusion in developing countries: social dynamics of São Paulo 
in the 1990s. Available from: http://www.dpi.inpe.br/geopro/papers/saopaulo_csiss.pdf [Accessed on 14 Jan 2006]  
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by cancer (22%), combined diabetes and hypertension 
(9%), osteoporosis (8%) and hepatitis (5%). Taking into 
account reporting on both isolated diabetes (37%) and 
diabetes linked to hypertension (9%), the results show 
that 46% of all legal cases related to patients affl icted 
with diabetes. 
With regard to the number of drugs per case, 43.5% 
(N=74) related to just one drug and 20% (N=34) request 
more than four drugs, generally prescribed by two or 
three health professionals.  
Table 1. Profi le of plaintiffs and origin of prescriptions from 
legal proceedings against the São Paulo Municipal Secretariat 
of Health, 2005. 
Variable N %
Sex 170 100
Female 108 63,5
Male 62 36,5
Age group (years) 88 100
0 - 9 13 14,8
10 - 19 14 15,9
20 - 29 11 12,5
30 - 39 2 2,3
40 - 49 5 5,7
50 - 59 10 11,4
60 - 69 8 9,1
70 - 79 21 23,9
80 and over 4 4,5
Occupation 105 100
Retired and pensioner 40 38,1
Unemployed 9 8,6
Student 12 11,4
Home maker 17 16,1
Other 27 25,7
Origin of prescription 120 100
SUS services 71 59,2
Municipal 31 25,8
Other 40 33,3
Private services 49 40,8
Contracted to SUS 16 13,3
Non-contracted 33 27,5
Legal Representation 124 100
Private 67 54,0
Independent lawyer 63 50,8
Lawyer within association 4 3,2
State 57 46,0
Government Ministry 11 8,9
Attorney General of the State 46 37,1
SUS – Brazilian Health System (in the Portuguese)
Figure 3. Legal proceedings for the procurement of drugs from 
the São Paulo Municipal Secretariat of Health, by index of 
social exclusion/ inclusion (Iex). São Paulo, 2005.
KEY
Districts
Sao Paulo Municipality
Legal Proceedings
Source: SMS-CE Info/GISA - January 2006
Figure 2. Classifi cation of medicines demanded in legal 
proceedings for the procurement of drugs from the São Paulo 
Municipal Secretariat of Health, according to supply from the 
Brazilian Health System (SUS). São Paulo, 2005.
REMUME: São Paulo Municipal Register of Essential Medicines
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%
Figure 1. Illnesses connected to legal proceedings against the 
São Paulo Municipal Secretariat of Health for procurement 
of drugs. Sao Paulo, 2005.
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The drugs from each case were classifi ed according 
to their availability through SUS, or in other words 
if they were publicly provided or not, as per Figure 
2. The diagram shows that 62% (N=282) of the items 
requested are listed as drugs from SUS programs, and 
as such appear on the REMUME – São Paulo or on 
the list of the Program for Exceptional Dispensation 
of Medicines (High Cost).
Medicines classifi ed as anti-cancer drugs, which represent 
7.2% of the total items requested generate expenditure 
of R$661,000 Brazilian Reais (approximately $281,000 
US Dollars), equivalent to 75% of total expenditure on 
the acquisition of medicines involved in legal proceed-
ings. Among these medicines, two are not registered in 
Brazil: genfi tinibe and erlotinibe. Qualitative evaluation 
of these items resulted in the list of medicines included 
in Table 2, for which research was carried out to test for 
evidence of their therapeutic effectiveness.
Among those not selected, which after a qualitative 
evaluation amounted to 59 specifi c pharmaceuticals, 
27% (N=16) do not have an alternative therapy avail-
able through REMUME and other SUS programs. The 
majority (73%) did, in principle, have a substitute for 
treatment. All were registered in Brazil.
Of the 133 cases for which the research form had been 
completed, 92% (N=122) include the residential ad-
dress of the plaintiff. Of these, 116 were distributed 
across the index of social exclusion/ inclusion in the 
Municipality of São Paulo (Iex). The remainder were 
not classifi ed because the addresses given in the court 
cases were found in other municipalities. Figure 3 
shows the result of the superimposition of the cases 
over the Iex map of the municipality. Of the plaintiffs 
whose addresses were given, 63% (N=73) reside in 
areas with an Iex of between -0.4 and 1, corresponding 
to the areas of São Paulo Municipality with lower levels 
of social exclusion.
DISCUSSION
One of the limitations of this present study stems from 
the inability to collect complete data from all the cases 
Table 2. Evaluation of the existence of evidences that support the use of anti-cancer drugs demanded in legal proceedings 
against the São Paulo Municipal Secretary of Health, 2005.
Drug Principal therapeutic use
Cochrane Library
(systematic review) Micromedex
Register
Effi ciency/effectiveness FDA Anvisa
Anastrozol Breast cancer with hormonal 
receptor in post-menopausal 
women 
Second choice of treatment 
for post-menopausal women11
Recommended in 
most cases
Yes Yes
Capecitabin Breast cancer Limited evidence4 Recommended in 
most cases
Yes Yes
Erlotinib Pancreatic cancer, cancer of 
the colon, cancer of the head 
and chest, renal cell cancer and 
ovarian cancer 
None Not recommended No No
Non-small cell lung cancer None Recommended in 
some cases
Yes No
Etoposide Non-small cell lung cancer Limited evidence7 Recommended in 
some cases
No Yes
Gefi tinib Non-small cell lung cancer None Recommended in 
some cases
Yes No
Imatinib Chronic myelogenous leukemia Limited evidence3 Recommended in 
most cases
Yes Yes
Letrozol Breast cancer with hormonal 
receptor in post-menopausal 
women
Second choice of treatment 
for post-menopausal women5
Recommended in 
most cases
Yes Yes
Mercaptopurin Acute lymphoid leukemia None Recommended in 
some cases
Yes Yes
Rituximab Non-Hodgkin lymphoma Limited evidence9 Recommended in 
some cases
Yes Yes
Temozolomide Cerebral anaplastic astrocytoma Limited evidence1 Recommended in 
most cases
Yes Yes
FDA: Food and Drug Administration
Anvisa: Brazilian Health Surveillance Agency 
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(22% lacking), since not all information was available 
at the SMS-SP Cabinet when the data were gathered. 
Some had been archived since the plaintiffs were al-
ready being attended by the State Health Secretariat or 
because they had died; others because the case has been 
sent to the Health Coordinator for the management of 
drugs which form part of REMUME and are available 
at the health units.
The greater chance that cases with a larger number of 
medicines from the REMUME list had originated from 
SUS services, and SMS-SP in particular, is related to the 
knowledge that these services have of the REMUME. 
The printed version of REMUME is available at all 
SMS-SP services. Thus, doctors responsible for pre-
scribing such services know exactly which medicines 
are available at the municipal SUS health units. This is 
not the case for doctors prescribing at private clinics, 
principally those which are not contracted under SUS. 
In the present study, 59% of prescriptions originated 
from SUS and 62% of medicines requested are on the 
list of SUS programs.
These incomplete cases which were not analyzed could 
have infl uenced the result of some variables such as 
residency of the plaintiff relative to the Iex and origin 
of prescription, since they make up 22% of the total 
number of court cases.
With regard to the variable for the origin of the pre-
scription, there is a greater probability that those cases 
with a greater number of medicines on the REMUME 
or other SUS lists had originated at services within the 
SUS system, and particularly SMS-SP. This is the case 
because the lists of medicines that can be found at these 
services are available at the health units for consulta-
tion by medical staff responsible for prescribing drugs. 
Since these incomplete cases that were not included in 
the analysis mostly originated from the Health Coordi-
nating Bodies, this implies that the drugs involved are 
listed on the REMUME and as such, there is a greater 
probability that the prescriptions originated in SUS. 
Thus, it is possible that the percentage of cases whose 
prescriptions came from SUS services is greater.
The inability to determine the social conditions of all 
plaintiffs also prevents a more in-depth analysis of verti-
cal equality. In spite of this, the present study furthers 
discussion about the effect of these cases on the PNM 
and the structure of the system.
In relation to the profi le of the plaintiffs, one possible 
explanation for the larger number of court cases brought 
by women is their greater concern about health, which 
in itself would be an incentive for them to be more 
interested in searching for other means to guarantee 
the supply of drugs that were prescribed to them. This 
could also be related to the fact that 74% of plaintiffs 
declared themselves to be retired, pensioners, unem-
ployed, students or home makers.
The greater number of cases brought by young people 
under the age of 19 could be associated with their 
increased consumption of medicines to treat serious 
defi ciencies and by older people because of the need 
to treat chronic illnesses.
It is not possible to say whether the services performed 
by providers contracted to SUS were carried out specifi -
cally for SUS, since these same providers offer services 
covered by various forms of health insurance provider. 
The fact that municipal services were responsible for 
26% of demand may indicate a failure in the Municipal 
Policy on Medicines, be it either on account of not 
guaranteeing access to essential medicines, or because 
health professionals in the municipal network did not 
abide by the REMUME.*
If on the one hand SUS services generate more income 
than they do law suits, on the other hand one would 
expect the main source of judicial support to be public 
(free legal support), which is not the case. A total of 
54% of the lawyers contracted by plaintiffs were pri-
vate. This subtle difference suggests that these people 
probably have suffi cient fi nancial leverage to pay legal 
charges. However, it is noteworthy that SUS services 
are being used to transfer prescriptions that had initially 
been written by private services, so as to bring a law 
suit against SMS-SP.
Cancer and diabetes were the illnesses most involved in 
the legal proceedings. The fact that they are both chronic 
diseases of relatively high cost may be cause for bring-
ing about law suits. This would also justify peoples’ 
willingness to pay for a lawyer, since if the medicine 
is subsequently received, the long-term fi nancial gain 
outweighs the initial legal costs.
The research showed that 62% of those medical items 
claimed appear on the medical lists of the SUS program. 
This percentage leads one to believe that at some stage 
a failure to guarantee access to drugs on the part of 
SMS-SP (REMUME) and of the state-level government 
(high-cost) could have occurred. Or, more probably, the 
health staff who prescribed or requested the drugs may 
not have had suffi cient knowledge about the availability 
of the medicines, bearing in mind that the majority 
of prescriptions came from SUS services that do not 
fall under SMS-SP (33%) or from private providers 
(41%). The supply of REMUME drugs (40% of items 
claimed) was made without committing any additional 
resources. This implies that SMS-SP expenditure on 
* São Paulo Municipal Secretariat of Health. Municipal list of essential medicines. São Paulo; 2004. Available from: http://ww2.prefeitura.
sp.gov.br//arquivos/secretarias/saude/ass_farmaceutica/0002/remune2004.pdf [Accessed on 17 Jan 2006]
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drug acquisition from legal cases applied to those 
classifi ed as High Cost, anti-cancer drugs, medicines 
whose dosage or pharmaceutical make-up differs from 
those listed in the REMUME (principle ingredients) 
and non-selected items.
The obligation of SMS-SP to procure anti-cancer drugs, 
which are supplied by SUS through centres for highly 
complex cancers, known as CACON, and the high cost 
that are involved in purchasing medicines show the 
considerable distortion that legal cases are causing to 
SUS. The normal supply of anti-cancer drugs through 
the system is linked to the integrated care provided 
to the patient in specialized centres, by means of the 
commitment of specifi c fi nancial resources. The basic 
failure to supply goes against the logic of integrated 
care, and diverts resources from the purchasing of medi-
cines used in primary care and medium-complexity care 
and forcing the incorporation of new technologies, the 
effectiveness of which may be doubtful.
Among the anti-cancer drugs awarded through legal 
proceedings, two have not even been registered in 
Brazil, while most have not yet undergone suffi cient 
controlled randomized clinical testing to prove their 
effectiveness. In summary, US$281,000 was spent in 
the acquisition of these medicines, not counting the cost 
of the participation of SUS, which anticipated meeting 
this demand in a different way. In addition to this, this 
money was spent on medicines that, for the most part, 
do not demonstrate signifi cant benefi ts to patients.
Another important point is that of the non-selected 
items, an alternative therapy was unavailable on RE-
MUME in only 27% of cases. Even in these instances, 
this does not mean that the illness would go totally un-
treated, since drugs made from other substances could 
be prescribed. For example, REMUME does not list 
alternatives to the angiotensin II receptor, but hyperten-
sion can be treated with enzyme inhibitor converters of 
angiotensin, among other treatments. This shows that 
these legal proceedings could have been avoided if the 
health professionals who had prescribed the drugs had 
referred to REMUME and/or if the judicial system 
had consulted the SMS-SP or independent specialists, 
before ordering the procurement of the drugs.
The observation that 63% of the plaintiffs involved in the 
court cases reside in municipal regions with a low degree 
of social exclusion is supported by the fi nding that most 
of these patients hired private legal representation. It also 
suggests that those who are bringing legal cases against 
the municipal government tend to be those least in need 
of social protection, and thus suggests that the legal 
proceedings do not support SUS’s aim of equality.
In this way, it is possible to point to factors, inherent 
in the legal claims for drugs, which go counter to the 
directives of both SUS and the PNM:
• Failure to recognize the tripartite responsibility 
within the system’s organization, such that SMS-SP 
acts as follows: it acquires drugs that are listed as 
being under state-level responsibility; it resolves 
judicial decisions for citizens from other munici-
palities; it purchases anti-cancer medication, which 
is supplied by means of integrated care to the patient 
through the private system;
• Procurement of drugs that are not listed on the Na-
tional Register of Essential Medicines (RENAME) 
or REMUME:
• Procurement of drugs prescribed by health profes-
sionals working in private clinics, while ignoring 
the principle of comprehensiveness in SUS care.
• Procurement of drugs not registered under An-
visa.
• Break down in attempts to ensure the rational use of 
drugs, which suggests that the choice of drugs is not 
given enough importance; supply of medicines that 
are different, but duplicated in terms of therapeutic 
effect, since the plaintiffs put forward several pre-
scriptions from different doctors and, on account of 
their demand for an immediate resolution, SMS-SP 
does not manage to question this before supply-
ing the drugs; failure to comply with therapeutic 
directives; procurement of drugs for which proof 
of their effectiveness and safety is unsubstantiated, 
and which are costly, even with the availability of 
substitutes that are effective, safe and have clearly 
defi ned cost-benefi t ratios;
• Less rationality in the use of public funds;
• Equality under threat.
The failure to consider these issues completely goes 
against the directive of rationality in the use of medi-
cines in Brazil, that was established by the PNM and 
by SUS directives.
With all the diffi culties involved in dealing with the 
waste of resources in the face of the growing demand 
for a universal health system, SUS is not failing to treat 
patients with cancer or diabetes (the diseases most com-
monly involved in the legal proceedings). A structured 
network already exists to treat these diseases and to 
provide the appropriate drugs. At issue is the demand 
for treatment for cancer or diabetes by means of medi-
cine A or B, for which there is often very little clear 
proof of its safety and effectiveness, which highlights 
preferences and implies that there is considerable infl u-
ence of market mechanisms. The imposition of legal 
proceedings has meant that SUS is procuring drugs that 
are not registered in Brazil.
To conclude, it is worth underscoring the strain that 
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these legal demands place on the management of SUS. 
The right of the citizen to demand, through the legal 
system, that access to drugs be guaranteed is fundamen-
tal to avoid any negligence by the State. However, to 
take as a starting point the assumption that any claim 
for medication should be met, since the right to health 
is guaranteed, reveals, in a pharmaceutical market of 
more than 15,000 specialized products, a lack of under-
standing of public health policies and the accompanying 
pharmaceutical management.12 The legal proceedings 
referred to here show that the PNM and its directives 
were not taken into consideration, in obvious contradic-
tion to the international trend for rationalizing the use 
of technologies in the area of health.2,8,10 The judicial 
system and the executive need to fi nd a joint solution so 
that the right of the Brazilian citizen to integrated care 
is guaranteed with safe and effective drugs that are cost 
effective, in line with the best and strongest scientifi c 
evidence available, without causing the distortions that 
are currently occurring.
